
SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease…
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease…
An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block…
For women with HER2 positive early-stage breast cancer taking Herceptin for six months could be…
Data released today from a large multi-center study provides a view into the effectiveness of…
By Joe Sutton, Edinburgh Napier University Cancer treatment is often highly effective at first, yet patients’ tumours…
Breast cancer patients who receive the drug herceptin for nine weeks as part of their…
Balveen Kaur, The Ohio State University and Pravin Kaumaya, The Ohio State University The human…
Testing for the activity of two genes could pick out women who are at increased…
A team of cancer researchers has uncovered one way certain tumours resist vital medication. In the…
The European Medicines Agency (EMA) has been informed that vials of Herceptin (trastuzumab), thought to…